All In Biotech

Drug Trial Radar · NCT06168383

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Jan 5, 2024

Primary completion

Dec 12, 2025

Study completion Jan 16, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

  • HSK31679 80mgDrug

    once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.

  • HSK31679 160mgDrug

    once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.

  • PlaceboDrug

    once daily, oral administration of placebo from Day 1 to Week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of patients(HSK31679-treated versus placebo-treated) with NASH improvement and with no worsening of fibrosis at week 52 compared with Baseline.Time frame: from Baseline to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital, Tsinghua University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.